PURPOSE: Primary central nervous system lymphomas (PCNSL) are rare tumours occurring in the brain. Their biology and the factors predicting survival are not well known. This study investigated expression of the antiapoptotic protein survivin and platelet-derived growth factor A (PDGF-A) and receptor (PDGFRalpha) in PCNSL. EXPERIMENTAL DESIGN: A total of 44 patients with histologically confirmed PCNSL treated between 1992 and 2004 were included in this study, and tumour specimens were investigated immunohistochemically for expression of survivin, PDGF-A and PDGFRalpha. Protein expression and clinical variables were analyzed statistically. RESULTS: Of the 44 tumours 43(98%) were diffuse large B-cell non-Hodgkin's lymphomas (NHL) and one was a T-cell NHL. Around 37 (84%) of the examined PCNSL specimens showed expression of survivin, 16 (36%) of PDGF-A and 34 (77%) of PDGFRalpha. Tumours expressing surviving co-expressed PDGFRalpha frequently and PDGF-A occasionally. Expression of the above proteins was not predictive for survival in this patient group. Except for age and therapy, no other clinical variables correlated significantly with overall survival. CONCLUSIONS: PCNSL express survivin and PDGFRalpha in the majority of investigated cases. PDGF-A is expressed less frequently. Immunohistochemical detection of these proteins does not correlate with overall survival and cannot be used as a prognostic factor.
PURPOSE:Primary central nervous system lymphomas (PCNSL) are rare tumours occurring in the brain. Their biology and the factors predicting survival are not well known. This study investigated expression of the antiapoptotic protein survivin and platelet-derived growth factor A (PDGF-A) and receptor (PDGFRalpha) in PCNSL. EXPERIMENTAL DESIGN: A total of 44 patients with histologically confirmed PCNSL treated between 1992 and 2004 were included in this study, and tumour specimens were investigated immunohistochemically for expression of survivin, PDGF-A and PDGFRalpha. Protein expression and clinical variables were analyzed statistically. RESULTS: Of the 44 tumours 43(98%) were diffuse large B-cell non-Hodgkin's lymphomas (NHL) and one was a T-cell NHL. Around 37 (84%) of the examined PCNSL specimens showed expression of survivin, 16 (36%) of PDGF-A and 34 (77%) of PDGFRalpha. Tumours expressing surviving co-expressed PDGFRalpha frequently and PDGF-A occasionally. Expression of the above proteins was not predictive for survival in this patient group. Except for age and therapy, no other clinical variables correlated significantly with overall survival. CONCLUSIONS: PCNSL express survivin and PDGFRalpha in the majority of investigated cases. PDGF-A is expressed less frequently. Immunohistochemical detection of these proteins does not correlate with overall survival and cannot be used as a prognostic factor.
Authors: Izidore S Lossos; Debra K Czerwinski; Ash A Alizadeh; Mark A Wechser; Rob Tibshirani; David Botstein; Ronald Levy Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Arnab Chakravarti; Elizabeth Noll; Peter McL Black; Daniel F Finkelstein; Dianne M Finkelstein; Nicholas J Dyson; Jay S Loeffler Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: C Adida; C Haioun; P Gaulard; E Lepage; P Morel; J Briere; H Dombret; F Reyes; J Diebold; C Gisselbrecht; G Salles; D C Altieri; T J Molina Journal: Blood Date: 2000-09-01 Impact factor: 22.113
Authors: T Kilic; J A Alberta; P R Zdunek; M Acar; P Iannarelli; T O'Reilly; E Buchdunger; P M Black; C D Stiles Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara Journal: Oncogene Date: 2000-02-03 Impact factor: 9.867
Authors: Kristina M Braaten; Rebecca A Betensky; Laurence de Leval; Yoshifumi Okada; Fred H Hochberg; David N Louis; Nancy L Harris; Tracy T Batchelor Journal: Clin Cancer Res Date: 2003-03 Impact factor: 12.531
Authors: Danielle Fortuna; D Craig Hooper; Amity L Roberts; Larry A Harshyne; Michelle Nagurney; Mark T Curtis Journal: PLoS One Date: 2018-10-31 Impact factor: 3.240